# US 2020/0002392 A1 · Treatment of retinitis pigmentosa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002392 A1
- Document ID: US20200002392A1
- Status: Published application
- Kind: A1
- Application number: 16/505,117
- Filed: 2019-07-08
- Published: 2020-01-02
- Earliest claimed: 2015-09-10
- Assignees: Oxford University Innovation Limited
- Applicants: Oxford University Innovation Limited
- Inventors: Robert MacLaren; Dominik Fischer
- Web page: https://patentgrep.com/patent/US20200002392A1

## CPC

- C07K 14/4702: {Regulators; Modulating activity}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N 15/86: Viral vectors
- C12Y 207/11014: Rhodopsin kinase (2.7.11.14)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14171: Demonstrated in vivo effect
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A polynucleotide comprising a nucleotide sequence encoding the retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15), wherein the RPGRORF15-encoding nucleotide sequence has been codon optimised to increase fidelity of replication of the sequence.

## Claims

### Claim 1

A composition comprising a nucleic acid comprising
(a) a sequence encoding a rhodopsin kinase promoter, and
(b) a sequence encoding a retinitis pigmentosa GTPase regulator ORF15 isoform (RPGRORF15) and comprising a nucleotide sequence that has at least 80% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the sequence encoding the promoter has at least 80% identity to the nucleic acid sequence of SEQ ID NO: 7.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the sequence encoding the promoter has at least 80% identity to the nucleic acid sequence of SEQ ID NO: 7.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the sequence encoding the promoter comprises the nucleic acid sequence of SEQ ID NO: 7.

### Claim 5 (depends on 2)

The composition of claim 2, wherein the sequence encoding the promoter comprises the nucleic acid sequence of SEQ ID NO: 7.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the sequence encoding the promoter consists of the nucleic acid sequence of SEQ ID NO: 7.

### Claim 7 (depends on 2)

The composition of claim 2, wherein the sequence encoding the promoter consists of the nucleic acid sequence of SEQ ID NO: 7.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 9 (depends on 2)

The composition of claim 2, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 10 (depends on 3)

The composition of claim 3, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 11 (depends on 4)

The composition of claim 4, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 12 (depends on 5)

The composition of claim 5, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 13 (depends on 6)

The composition of claim 6, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 14 (depends on 7)

The composition of claim 7, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence encoding an amino acid sequence that has at least 80% identity to the amino acid sequence of SEQ ID NO: 1.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 16 (depends on 2)

The composition of claim 2, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 17 (depends on 3)

The composition of claim 3, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 18 (depends on 4)

The composition of claim 4, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 19 (depends on 5)

The composition of claim 5, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 20 (depends on 6)

The composition of claim 6, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.

### Claim 21 (depends on 7)

The composition of claim 7, wherein the sequence encoding the RPGRORF15 comprises a nucleotide sequence that has at least 97% identity to the nucleic acid sequence of SEQ ID NO: 3.
